The American College of Gastroenterology has released recommendations of preferred approaches for diagnosing and evaluating patients with abnormal liver test results.
A 50-year-old man presents to the emergency department with abdominal pain, nausea, jaundice, and dark urine.
A patient's positive hepatitis B results were overlooked for 7 years.
A greater understanding of the healthcare issues specific to the lesbian, gay, bisexual, and transgender community may improve the quality of care.
More than half of Americans polled were unsure or unaware of the existence of a hepatitis B vaccine.
No reports of adverse events with intradermal recombinant HBsAg-based vaccine.
Nearly all pregnant women with hepatitis B virus (HBV) taking telbivudine had undetectable levels of HBV DNA in cord blood.
The combination of entecavir and birinapant eradicated the hepatitis B virus in preclinical trials.
Strengthening current hepatitis B virus prevention and treatment efforts can reduce related mortality.
Immunosuppressive agents do not increase the risk of HCV flares in anti-HCV-positive lupus patients.
Overall survival was significantly improved for patients treated with nucleoside analogues (NAs) versus those who received no NAs.
Daclatasvir plus sofosbuvir demonstrated a sustained virological response in 98% of patients with genotype 1 hepatitis C infection.
Projects funded by the grant will aid public health efforts to reduce the burden of viral hepatitis in the United States.
A community-based organization focused on eliminating hepatitis-related health disparities issued a report detailing improvements that can be made for better hepatitis care.
The risk-benefit profile of more widespread hepatitis C screening is not sufficiently understood, researchers suggest.
Researchers have eliminated hepatitis C as the cause of impaired mental function in HIV patients.
To prevent reactivation, appropriate antiviral therapy should be given to patients who are found to be HBsAg positive.
Combination simeprevir and sofosbuvir has been approved by the FDA for treatment of chronic genotype 1 hepatitis C.
Fatty liver disease and other topics gained traction at the AASLD Annual Meeting as HCV therapy research plateaus.
Patients at risk for HBV infection include HIV-positive individuals, injection-drug users, and household contacts of those with HBV.
Identifying more patients with chronic hepatitis B virus, and increasing treatment, monitoring and drug adherence could translate to health gains.
Several dermatologic manifestations of hepatitis C infection have been described.
All should be vaccinated and undergo serologic testing
The FDA is updating the labels for two drugs to warn about the risk for immunosupression-related hepatitis B virus reactivation.
What is the standard of care for a patient with elevated liver function tests?
Illness possibly related to "Townsend Farms Organic Anti-Oxidant Blend" frozen berry, pomegranate mix.
Hepatitis B virus infection does not disqualify health-care workers from working.
If the treatment goal of viral eradicatication cannot be met, strive to slow disease progression, lower risk of liver cancer, and improve quality of life.
New recommendations state that all patients with HIV be treated with antiretroviral therapy (ART) regardless of CD4 cell count.
The CDC's Advisory Committee on Immunization Practices recommends hepatitis B virus vaccine for all unvaccinated patients aged 19 through 59 years with diabetes.